Weekend News: Business, Finance and Innovations in Biotech and Pharma Industries


MPP Licences Nine Companies to Develop Generic Version of HIV and Hep C Treatment

New generic manufacturing licences were signed for four antiretrovirals and hepatitis C direct-acting antiviral-daclatasvir by the Medicines Patent Pool (MPP). Total nine new sub-licensing agreements were signed with Aurobindo, Desano, Emcure, Hetero Labs, Laurus Labs, Lupin and new partner, Ahmedabad based Zydus Cadila for the production of those generic versions of HIV and hepatitis C treatment which are in the priority list of World Health Organization (WHO).

Currently, 13 generic manufacturing partners of MPP are involved in more than 60 projects for the development of treatments in developing countries for both children and adults.

These new sub-licences will secure greater volumes of low-cost medicines for people living with HIV and hepatitis C in low- and middle-income countries,” said Greg Perry, MPP’s Executive Director. “We look forward to working with the companies to speed delivery of these treatments to those most in need of better medical options”.


Aprecia got Fund to Develop 3D Printed Fast Melt Medications

US based Aprecia Pharmaceuticals signed a debt financing agreement with Hercules Capital Inc. of up to $30 million. The company utilizes proprietary ZipDose® technology platform to manufacture fast melt pharmaceutical formulations.  

Under the agreement, the company has received an initial amount of $20 million which will be used to purchase additional manufacturing equipments and to fund the development and approval of Aprecia’s pipeline candidates.

SPRITAM is the first FDA approved candidate of Aprecia developed by the 3D printing technology. It was first commercially launched in March 2016.


Pfizer’s Sutent showed Promising Phase III Results for Kidney Cancer

Pfizer’s cancer drug, Sutent showed improved disease-free survival (DFS) in patients suffering from renal cell carcinoma (RCC) who are at a high risk of recurrence after surgery, in Phase III clinical trial S-TRAC (Sunitinib Trial in Adjuvant Renal Cancer).

RCC is one of the most common types of kidney cancer. The S-TRAC was the first RCC clinical trial of a tyrosine kinase inhibitor. According to the company, the adjuvant therapy assists in  lowering of the risk of cancer recurrence in early stage cancer patients.

Pfizer, Chief Development Officer, Oncology, Global Product Development, Mace Rothenberg, said, “SUTENT has long been a standard of care for the treatment of advanced RCC, and has reached more than 250,000 patients across diagnoses around the world since its initial approval 10 years ago. We believe the results from the S-TRAC trial support the potential for SUTENT to be a treatment option in a broader range of patients. We look forward to sharing the detailed results of S-TRAC with the oncology community and discussing these data with health authorities to determine an appropriate regulatory path forward“.

Featured image credit: Official match balls of the UEFA EURO 2016 Tournament © katatonia82 (Stock Photo ID: 131344157)

Leave a reply

Your email address will not be published. Required fields are marked *